Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PFE
stocks logo

PFE

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
13.43B
+1.14%
0.563
-6.14%
17.07B
-3.58%
0.867
-18.22%
18.03B
+1.5%
0.707
+12.23%
Estimates Revision
The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -0.66% over the past three months. During the same period, the stock price has changed by -13.36%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.67%
In Past 3 Month
Stock Price
Go Down
down Image
-13.36%
In Past 3 Month
18 Analyst Rating
up Image0
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 27.81 USD with a low forecast of 23.00 USD and a high forecast of 32.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
13 Hold
0 Sell
Moderate Buy
up Image0
Current: 23.090
sliders
Low
23.00
Averages
27.81
High
32.00
up Image0
Current: 23.090
sliders
Low
23.00
Averages
27.81
High
32.00
UBS
Trung Huynh
Hold
Maintains
$24 → $25
2025-04-30
Reason
UBS
Trung Huynh
Price Target
$24 → $25
2025-04-30
Maintains
Hold
Reason
UBS analyst Trung Huynh raised the firm's price target on Pfizer to $25 from $24 and keeps a Neutral rating on the shares. While Pfizer had a "mixed" revenue performance, cost savings were significant, the analyst tells investors in a research note.
Cantor Fitzgerald
Carter Gould
Hold
Initiates
$24
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
$24
2025-04-22
Initiates
Hold
Reason
Cantor Fitzgerald analyst Carter Gould initiated coverage of Pfizer with a Neutral rating and $24 price target. Pfizer made "concrete progress" on its cost-base and margins over 2024, but still underperformed the market for the sixth time in seven years as the upcoming stacking of losses of exclusivity has been an anticipated headwind for "the better part of a decade," the analyst tells investors. The firm still sees consensus that as "overly optimistic" on its views of erosion curves and under-appreciative of competitive pressures on Vyndamax and Prevnar, the analyst added.
Goldman Sachs
Asad Haider
Strong Buy
to
Hold
Downgrades
$32 → $25
2025-04-08
Reason
Goldman Sachs
Asad Haider
Price Target
$32 → $25
2025-04-08
Downgrades
Strong Buy
to
Hold
Reason
Goldman Sachs downgraded Pfizer to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The firm says that on the back of a challenging past two years which the company saw downward revisions around COVID related revenue expectations, it expects the shares to remain rangebound. Pfizer faces base business pressure, with greater clarity needed on acquisitions and pipeline levers required to necessitate a sustained stock re-rating, the analyst tells investors in a research note.
UBS
Trung Huynh
Hold
Maintains
$28 → $24
2025-04-08
Reason
UBS
Trung Huynh
Price Target
$28 → $24
2025-04-08
Maintains
Hold
Reason
UBS analyst Trung Huynh lowered the firm's price target on Pfizer to $24 from $28 and keeps a Neutral rating on the shares. The firm says Q1 consensus numbers on Paxlovid and Comirnaty appear too high, but if danuglipron data is disclosed on the day of Q1 results, danu moving into a large Phase 3 obesity program would negate a poor quarter, the analyst tells investors in a research note. UBS says it needs to see a stabilizing tail from the COVID business, continued growth in key assets, and execution on the pipeline to become more constructive on the name.
Guggenheim
Vamil Divan
Strong Buy
Reiterates
n/a
2025-03-18
Reason
Guggenheim
Vamil Divan
Price Target
n/a
2025-03-18
Reiterates
Strong Buy
Reason
Guggenheim
Vamil Divan
Strong Buy
Reiterates
n/a
2025-03-12
Reason
Guggenheim
Vamil Divan
Price Target
n/a
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pfizer Inc (PFE.N) is 7.97, compared to its 5-year average forward P/E of 12.69. For a more detailed relative valuation and DCF analysis to assess Pfizer Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
12.69
Current PE
7.97
Overvalued PE
18.88
Undervalued PE
6.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
9.89
Current EV/EBITDA
7.23
Overvalued EV/EBITDA
13.39
Undervalued EV/EBITDA
6.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
3.08
Current PS
2.06
Overvalued PS
3.68
Undervalued PS
2.47

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 221.88% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

PFE News & Events

Events Timeline

(ET)
2025-05-21
14:27:04
RFK Jr.'s MAHA Report expected to criticize food additives, vaccines, WSJ says
select
link
2025-05-20 (ET)
2025-05-20
13:31:06
CMS demands on drug pricing 'extreme,' 'highly problematic,' says Leerink
select
2025-05-20
13:30:46
HHS says 'taking immediate steps to implement' Trump drug pricing order
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
05-22SeekingAlpha
PinnedPfizer bid to expand Talzenna use in prostate cancer questioned by FDA panel

  • FDA Panel Rejects Pfizer's Expansion Request: A U.S. FDA advisory panel declined Pfizer's request to broaden the patient population for its prostate cancer treatment Talzenna, citing insufficient data and concerns about the benefits being potentially random.

  • Current Approval Status: Talzenna is currently approved for patients with castration-resistant prostate cancer who have the HRR gene mutation, and the proposed expansion would significantly increase the number of eligible patients.

Preview
8.5
05-20Benzinga
PinnedPfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal

  • Pfizer's Acquisition of SSGJ-707: Pfizer Inc. has secured exclusive global rights to 3SBio Inc.'s bispecific antibody SSGJ-707, with a deal potentially worth up to $6 billion, including a $1.25 billion upfront payment and additional milestone payments.

  • Clinical Trials and Manufacturing Plans: The drug, currently in clinical trials for various cancers in China, will see Pfizer handle global manufacturing and commercialization (excluding China) and plans to initiate Phase 3 trials in 2025.

Preview
9.0
05-22SeekingAlpha
Prices of new U.S. drugs doubled over the past four years: report

  • Rising Drug Prices: A Reuters analysis reveals that the median annual list price of newly launched medications in the U.S. has more than doubled from 2021 to 2024, exceeding $370K, largely due to a focus on rare disease therapies which command premium prices.

  • Orphan Drug Market Growth: The proportion of new drugs targeting orphan diseases has increased significantly, from 51% in 2019 to 72% in 2024, with notable high-priced gene therapies like Lenmeldy and PTC's therapy leading the market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pfizer Inc (PFE) stock price today?

The current price of PFE is 23.09 USD — it has increased 0.22 % in the last trading day.

arrow icon

What is Pfizer Inc (PFE)'s business?

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

arrow icon

What is the price predicton of PFE Stock?

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 27.81 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pfizer Inc (PFE)'s revenue for the last quarter?

Pfizer Inc revenue for the last quarter amounts to 13.72B USD, decreased -7.82 % YoY.

arrow icon

What is Pfizer Inc (PFE)'s earnings per share (EPS) for the last quarter?

Pfizer Inc. EPS for the last quarter amounts to 0.52 USD, decreased -5.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pfizer Inc (PFE)'s fundamentals?

The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -0.66% over the past three months. During the same period, the stock price has changed by -13.36%.
arrow icon

How many employees does Pfizer Inc (PFE). have?

Pfizer Inc (PFE) has 88000 emplpoyees as of May 23 2025.

arrow icon

What is Pfizer Inc (PFE) market cap?

Today PFE has the market capitalization of 130.99B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free